Statement: FDA Must Reject Tanezumab as a Treatment for Osteoarthritis Due to Unacceptable Dangers, Little to No Benefit
Table of Foreign Investor-State Cases and Claims Under NAFTA and Other U.S. “Trade Deals” January 15, 2021
ISDS Case Study: RDC v. Guatemala: CAFTA Investor-State Ruling: Tribunal Ignores CAFTA Annex, Cites Another Tribunal to Rule against Guatemala July 19, 2012